The FDA on Monday approved an experimental drug that aims to slow the progression of Alzheimer's disease, despite the fact that a key FDA panel late last year said that questions remain about its effectiveness.
The FDA on Monday approved the use of aducanumab in patients in the early stages of Alzheimer's.
Drugmakers Biogen and Eisai say the drug doesn't just address symptoms but actually slows the progression timeline of the disease.
WCPO 9 anchor Adrian Whitsett talks to geriatric psychiatrist Dr. Stephen Wilkes at the Mercy Health Hospital in Batavia about who this drug would benefit.